Centrum Badan Klinicznych PI-House sp. z o.o.

Gdynia 81-553

0 studies enrolling now · 1 studies all time

What they study most

Atopic Dermatitis

Studies at this site

• Long-term Safety and Efficacy Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis (ADjoin) — Completed